Skip Nav Destination
            
    
            
 
    
    
        
            
                
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                     
    
                     
    
                    
        
                    
        
        Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
        
        
                    
                
            
    
    
    
        
        
     
    
                    
        
                    
                
            
    
    
    
        
                    
                
            
    
    
    
        
        
        
        
     
    
                    
        
                    
                
            
    
    
    
        
        
     
    
                     
    
                     
    
                    
        
                    
        
        Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
                    
                
            
    
    
    
                    
                
            
    
    
    
        
                    
                
            
    
    
    
                    
        
        Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
                    
                
            
    
    
    
                    
        
        Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
    
        
    
    
    
            
        
            
    
        
        
    
             
            
             
            
             
        
    
 
    
    
 
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
Table of Contents
DRUG ADVANCES
SYSTEMATIC REVIEW
CLINICAL TRIALS AND OBSERVATIONS
        
        Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Paul Lesueur,Gandhi Damaj,Khê Hoang-Xuan,Virginie Roland,Anna Schmitt,Olivier Chinot,Michel Fabbro,Philippe Agapé,Cécile Moluçon-Chabrot,Safia Chebrek,Agusti Alentorn,Loic Feuvret,Daniel Delgadillo,Dinu Stefan,Sylvain Choquet,Lucia Nichelli,Karima Mokhtari,Bertrand Mathon,Sylvain Dureau,Carole Soussain,Caroline Houillier
            
        
    
            IMMUNOBIOLOGY AND IMMUNOTHERAPY
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
            Fotini Vogiatzi,Julia Heymann,Kristina Müller,Dorothee Winterberg,Aneta Drakul,Thies Rösner,Lennart Lenk,Michelle Heib,Carina Lynn Gehlert,Gunnar Cario,Martin Schrappe,Alexander Claviez,Beat Bornhauser,Jean-Pierre Bourquin,Simon Bomken,Dieter Adam,Fabian-Simon Frielitz,Britta Maecker-Kolhoff,Martin Stanulla,Thomas Valerius,Matthias Peipp,Christian Kellner,Denis M. Schewe
            
        
    
            LYMPHOID NEOPLASIA
A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile
            Julia Salmeron-Villalobos,Caoimhe Egan,Vanessa Borgmann,Inga Müller,Blanca Gonzalez-Farre,Joan Enric Ramis-Zaldivar,Dominik Nann,Olga Balagué,Mónica López-Guerra,Dolors Colomer,Ilske Oschlies,Wolfram Klapper,Selina Glaser,Young Hyeh Ko,Irina Bonzheim,Reiner Siebert,Falko Fend,Stefania Pittaluga,Elias Campo,Itziar Salaverria,Elaine S. Jaffe,Leticia Quintanilla-Martinez
            
        
    
            Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma
            Anthony R. Colombo,Monirath Hav,Mohan Singh,Alexander Xu,Alicia Gamboa,Tucker Lemos,Erik Gerdtsson,Denaly Chen,Jane Houldsworth,Rita Shaknovich,Tomohiro Aoki,Lauren Chong,Katsuyoshi Takata,Elizabeth A. Chavez,Christian Steidl,James Hicks,Peter Kuhn,Imran Siddiqi,Akil Merchant
            
        
    
            MYELOID NEOPLASIA
HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition
            Céline Moison,Jean-François Spinella,Jalila Chagraoui,Vincent-Philippe Lavallée,Bernhard Lehnertz,Clarisse Thiollier,Isabel Boivin,Nadine Mayotte,Tara MacRae,Anne Marinier,Josée Hébert,Guy Sauvageau
            
        
    
            PLATELETS AND THROMBOPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
        
        Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Marie Robin,Raphael Porcher,David Michonneau,Laetitia Taurines,Flore Sicre de Fontbrune,Aliénor Xhaard,Bastien Oriano,Aurélien Sutra Del Galy,Régis Peffault de Latour,Gérard Socié,Marie-Hélène Schlageter
            
        
    
            RESEARCH LETTERS
The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
            Isabel Juliana F. Hofman,Teresa Mortera-Blanco,Pedro Luis Moura,Johanna Vestlund,Sigita Venckute Larsson,Edda M. Elvarsdottir,Gunilla Walldin,Magnus Tobiasson,Birgitta Sander,Marios Dimitriou,Sten-Eirik W. Jacobsen,Petter S. Woll,Martin Jädersten,Eva Hellström-Lindberg
            
        
    
            CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
            Khushnuma Mullanfiroze,Arina Lazareva,Jan Chu,Lindsey Williams,Saskia Burridge,Juliana Silva,Robert Chiesa,Kanchan Rao,Giovanna Lucchini,Sara Ghorashian,Maeve O’Reilly,Ben Carpenter,Victoria Grandage,Rachael Hough,Claire Roddie,Persis J. Amrolia
            
        
    
            Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
            Kai Rejeski,Andreas Burchert,Gloria Iacoboni,Pierre Sesques,Lars Fransecky,Veit Bücklein,Corinna Trenker,Rafael Hernani,Ralph Naumann,Jonas Schäfer,Viktoria Blumenberg,Christian Schmidt,Kristina Sohlbach,Michael von Bergwelt-Baildon,Emmanuel Bachy,Pere Barba,Marion Subklewe
            
        
    
            
        
        Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Juan P. Alderuccio,Weiyun Z. Ai,John Radford,Melhem Solh,Kirit M. Ardeshna,Matthew A. Lunning,Brian T. Hess,Pier L. Zinzani,Anastasios Stathis,Carmelo Carlo-Stella,Mehdi Hamadani,Brad S. Kahl,David Ungar,Turk Kilavuz,Eric Yu,Yajuan Qin,Paolo F. Caimi
            
        
    
            COMMENTARIES
Revision of RUNX1 variant curation rules
            Simone Feurstein,Xi Luo,Mancy Shah,Taylor Walker,Nikita Mehta,David Wu,Lucy A. Godley,on behalf of the Myeloid Malignancy Variant Curation Expert Panel
            
        
    
            
        
        Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Ulrich Jaeger,Constantine S. Tam,Peter Borchmann,Joseph P. McGuirk,Marianne Johansen,Edmund K. Waller,Samantha Jaglowski,Charalambos Andreadis,Stephen R. Foley,Jason R. Westin,Isabelle Fleury,P. Joy Ho,Stephan Mielke,Takanori Teshima,Gilles Salles,Stephen J. Schuster,Fiona He,Richard T. Maziarz,Sebastian Mayer,Shinichi Makita,Marie J. Kersten,Monalisa Ghosh,Nina Wagner-Johnston,Koji Kato,Paolo Corradini,Hideki Goto,Silvia Colicino,Abhijit Agarwal,Chiara Lobetti-Bodoni,Michael R. Bishop
            
        
    
            ERRATUM
- 
        
            Cover Image
        
        Cover Image![issue cover]()  The in situ spatial distribution of malignant cells within the tumor microenvironment in diffuse large B-cell lymphoma is classified by their distance to the immune interface using imaging mass cytometry. See the article by Colombo et al. 
- PDF Icon Front MatterFront Matter
- PDF Icon Editorial BoardEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals
 
                    
















